Usage: Imdelltra is indicated for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
Usage: Imfinzi is a PD-L1 antibody indicated for adults with NSCLC (resectable, unresectable Stage III, or metastatic), limited- and extensive-stage SCLC, biliary tract cancer, unresectable hepatocellular carcinoma, dMMR endometrial cancer, muscle-invasive bladder cancer, and resectable gastric/GEJ adenocarcinoma. Administered as monotherapy or with chemotherapy.
Usage: Tecentriq is a PD-L1 blocking antibody indicated for non-small cell lung cancer (adjuvant and metastatic), extensive-stage small cell lung cancer, unresectable or metastatic hepatocellular carcinoma, BRAF V600 mutation-positive melanoma, and alveolar soft part sarcoma in adults and pediatric patients 2 years and older.
Usage: Zepzelca treats adults with small cell lung cancer: as maintenance therapy (with atezolizumab) for extensive-stage SCLC after first-line induction, and for metastatic SCLC that progressed on or after platinum-based chemotherapy (accelerated approval).